Get the Stockscreener App
0.3399
4.31%
-0.0153
After Hours:
.33
-0.0099
-2.91%
Co Diagnostics Inc stock is traded at $0.3399, with a volume of 68,546.
It is down -4.31% in the last 24 hours and up +1.77% over the past month.
Co-Diagnostics Inc is a molecular diagnostics company. It develops, licenses, and commercializes molecular technologies such as lab systems (MDx device) and manufacture and sell reagents used for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). CDI's low-cost system uses its tests to diagnose tuberculosis, Zika, hepatitis B and C, Malaria, dengue and HIV.The Company's technologies are utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests for its Co-Dx PCR platform and to locate genetic markers for use in applications other than infectious diseases.
See More
Previous Close:
$0.3552
Open:
$0.345
24h Volume:
68,546
Relative Volume:
0.38
Market Cap:
$12.35M
Revenue:
$7.11M
Net Income/Loss:
$-41.28M
P/E Ratio:
-0.2463
EPS:
-1.38
Net Cash Flow:
$-26.84M
1W Performance:
-7.61%
1M Performance:
+1.77%
6M Performance:
-70.18%
1Y Performance:
-72.37%
1-Day Range:
$0.3301
$0.3566
1-Week Range:
$0.3301
$0.3775
52-Week Range:
$0.2801
$2.2299
Co Diagnostics Inc Stock (CODX) Company Profile
Name
Co Diagnostics Inc
Sector
Industry
Phone
(801) 278-9769
Address
4049 SOUTH HIGHLAND DRIVE, SALT LAKE CITY
Compare CODX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CODX
Co Diagnostics Inc
|
0.3399 | 12.35M | 7.11M | -41.28M | -26.84M | -1.38 |
|
ABT
Abbott Laboratories
|
133.24 | 231.09B | 42.34B | 13.50B | 6.66B | 7.71 |
|
BSX
Boston Scientific Corp
|
102.86 | 155.24B | 17.55B | 2.03B | 2.72B | 1.37 |
|
SYK
Stryker Corp
|
380.92 | 144.54B | 23.22B | 2.86B | 3.58B | 7.40 |
|
MDT
Medtronic Plc
|
83.48 | 108.82B | 33.20B | 4.26B | 5.47B | 3.29 |
|
EW
Edwards Lifesciences Corp
|
73.68 | 44.31B | 5.54B | 4.18B | 623.10M | 7.00 |
Co Diagnostics Inc Stock (CODX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-12-22 | Downgrade | Sidoti | Buy → Neutral |
| Dec-29-21 | Initiated | Sidoti | Buy |
| Mar-29-21 | Downgrade | Maxim Group | Buy → Hold |
| May-20-20 | Upgrade | Maxim Group | Hold → Buy |
| May-18-20 | Reiterated | H.C. Wainwright | Buy |
| Mar-09-20 | Reiterated | H.C. Wainwright | Buy |
| Mar-03-20 | Downgrade | Maxim Group | Buy → Hold |
View All
Co Diagnostics Inc Stock (CODX) Latest News
Co-Diagnostics, Inc. (NASDAQ:CODX) Q1 2025 Earnings Call Transcript - Insider Monkey
Earnings call transcript: Co-Diagnostics Q1 2025 shows improved EPS and revenue decline - Investing.com Nigeria
Co-Diagnostics Q1 2025 Earnings Call Transcript - MarketBeat
Co-Diagnostics Inc (CODX) Q1 2025 Earnings Call Highlights: Strategic Advancements Amid Revenue ... - Yahoo Finance
Co-Diagnostics Reports Q1 2025 Financial Results - TipRanks
Co-Diagnostics, Inc. (CODX) Reports Q1 Loss, Misses Revenue Estimates - MSN
Co-Diagnostics Inc Reports Q1 2025 Earnings: EPS Loss of $0.24 Beats Estimates, Revenue Falls Short at $0.1 Million - GuruFocus
Co-Diagnostics, Inc. Reports First Quarter 2025 Financial Results - The Manila Times
Examining the Future: Co-Diagnostics's Earnings Outlook - Nasdaq
Co-Diagnostics (NASDAQ:CODX) Stock Rating Upgraded by D Boral Capital - Defense World
D. Boral Capital Initiates Coverage of Co-Diagnostics (LSE:0A50) with Buy Recommendation - Nasdaq
Co-Diagnostics, Inc. Announces First Quarter 2025 Earnings Relea - GuruFocus
Co-Diagnostics, Inc. Announces First Quarter 2025 Earnings Release Date and Webcast - GlobeNewswire
Co-Diagnostics Q1 2025 Earnings Coming May 8: Key Executive Team to Present Latest Financial Performance - Stock Titan
Stock Market Recap: Co-Diagnostics Inc (CODX) Concludes at 0.32, a -18.26 Surge/Decline - DWinneX
Co-Diagnostics (NASDAQ:CODX) Now Covered by Analysts at D. Boral Capital - Defense World
Co-Diagnostics expands sales agreement, adds Clear Street as agent By Investing.com - Investing.com Canada
Co-Diagnostics expands sales agreement, adds Clear Street as agent - Investing.com Australia
This Kohl's Analyst Begins Coverage On A Bearish Note; Here Are Top 5 Initiations For Monday - Benzinga
D. Boral Capital Initiates Coverage of Co-Diagnostics (CODX) with Buy Recommendation - Nasdaq
Co-Diagnostics, Inc. to Present at 16th Next Generation Dx Summit in Washington, D.C. - Seeking Alpha
Co-Diagnostics, Inc. Reports First Quarter 2024 Financial Results - Seeking Alpha
Co-Diagnostics Inc (NASDAQ: CODX): Is This The Time To Buy? - Marketing Sentinel
Co-Diagnostics stock hits 52-week low at $0.28 amid market challenges - Investing.com Canada
Co-Diagnostics stock hits 52-week low at $0.28 amid market challenges By Investing.com - Investing.com South Africa
All You Need to Know About CoDiagnostics (CODX) Rating Upgrade to Buy - Yahoo Finance
Co-Diagnostics targets 2025 clinical evaluations for TB and HPV tests in India and South Africa - MSN
Co-Diagnostics Earnings Call: Progress Amid Challenges - MSN
HC Wainwright Lowers Co-Diagnostics (NASDAQ:CODX) Price Target to $1.00 - Defense World
Co-Diagnostics, Inc. (CODX) Reports Q4 Loss, Misses Revenue Estimates - MSN
Co-Diagnostics Full Year 2024 Earnings: Misses Expectations - Yahoo Finance
Co-Diagnostics, Inc. (NASDAQ:CODX) Q4 2024 Earnings Call Transcript - Insider Monkey
Earnings call transcript: Co-Diagnostics sees revenue dip, losses deepen in Q4 2024 By Investing.com - Investing.com South Africa
Co-Diagnostics operating loss hits USD 40.1M in FY 24 - Medical Buyer
Co-Diagnostics Inc (CODX) Q4 2024 Earnings Call Highlights: Navigating Challenges with ... - Yahoo Finance
Co-Diagnostics Inc (CODX) Q4 2024 Earnings Call Highlights: Navi - GuruFocus
Co-Diagnostics Inc (CODX) Q4 2024 Earnings Call Highlights: Navigating Challenges with ... By GuruFocus - Investing.com Canada
Co-Diagnostics Reports 2024 Financial Results and Strategic Progress - TipRanks
Co-Diagnostics, Inc. Reports Full Year 2024 Financial Results - Lelezard
Co-Diagnostics Inc Reports $3.9 Million Revenue and $1.24 EPS Lo - GuruFocus
Co-Diagnostics earnings missed by $0.03, revenue fell short of estimates - Investing.com
Co-Diagnostics (CODX) Highlights 2024 Earnings and Strategic Dev - GuruFocus
Earnings call transcript: Co-Diagnostics sees revenue dip, losses deepen in Q4 2024 - Investing.com India
Co-Diagnostics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Co Diagnostics Inc Stock (CODX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.11%
0.79%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):